Company Name: | ResMed Inc | | Ticker Symbol: | RMD | CIK Number: | 0000943819 | WWW Address: | http://www.resmed.com |
CEO: | Mr. Michael J. (Mike) Farrell | No. of Employees: | 6,080 |
Common Issue Type: | CS | Business Description: | ResMed Inc. is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.
|
| | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | 100.43 | -0.74 | - | - | 100.9 | 101.61 | 99.84 | 96632 |
Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
14,354.2 | 142.9 | 0.00 | 2.42 | 1.40 | 40.7 | 1.4 | 104.78 - 67.04 |
| KEY FIGURES (Latest Twelve Months - LTM) | Yesterday's Close | 101.19 | $ | PE Ratio - LTM | 40.7 | |
Market Capitalisation | 14,354.2 | mil |
Latest Shares Outstanding | 142.9 | mil |
Earnings pS (EPS) | 2.42 | $ |
Dividend pS (DPS) | 1.40 | ¢ |
Dividend Yield | 1.4 | % |
Dividend Payout Ratio | 1 | % |
Revenue per Employee | 339,924 | $ |
Effective Tax Rate | 0.2 | % |
Float | 140.9 | mil |
Float as % of Shares Outstanding | 1.0 | % |
Foreign Sales | | mil |
Domestic Sales | | mil |
Selling, General & Adm/tive (SG&A) as % of Revenue | 0.30 | % |
Research & Devlopment (R&D) as % of Revenue | 0.10 | % |
Gross Profit Margin | 58.1 | % |
EBITDA Margin | 27.1 | % |
Pre-Tax Profit Margin | 0.0 | % |
Assets Turnover | 61.4 | % |
Return on Assets (ROA) | 10.2 | % |
Return on Equity (ROE) | 18.7 | % |
Return on Capital Invested (ROCI) | 12.5 | % |
Current Ratio | 4.6 | |
Leverage Ratio (Assets/Equity) | 1.8 | |
Interest Cover | 15.8 | |
Total Debt/Equity (Gearing Ratio) | 0.55 | |
LT Debt/Total Capital | 35.0 | % |
Working Capital pS | 8.98 | $ |
Cash pS | 0.00 | $ |
Book-Value pS | 14.13 | $ |
Tangible Book-Value pS | 4.43 | $ |
Cash Flow pS | 3.03 | $ |
Free Cash Flow pS | 2.51 | $ |
 |
KEY FIGURES (LTM): Price info |
Price/Book Ratio | 7.00 | |
Price/Tangible Book Ratio | 0.00 | |
Price/Cash Flow | 32.6 | |
Price/Free Cash Flow | 39.4 | |
P/E as % of Industry Group | 104.0 | % |
P/E as % of Sector Segment | 84.0 | % |
| | Balance Sheet (at a glance) in Millions |
| | | DIVIDEND INFO | Type of Payment | Cash Payment |
Dividend Rate | 1.40 |
Current Dividend Yield | 1.4 |
5-Y Average Dividend Yield | 0.0 |
Payout Ratio | 1.0 |
5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | Share price performance previous 3 years |
| 
|  | Share price performance intraday |
| 
| | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
1 Week | - | - | - | 4.4 | 2 | 499,994 | 1,286,938 |
4 Weeks | 101.61 | 92.92 | 98.38 | 2.4 | 2 | 516,051 | 10,321,023 |
13 Weeks | 104.78 | 87.10 | 88.72 | 13.5 | 16 | 621,870 | 39,799,680 |
26 Weeks | 104.78 | 77.71 | 78.87 | 27.7 | 22 | 563,252 | 70,406,575 |
52 Weeks | 104.78 | 67.04 | 69.09 | 45.8 | 30 | 588,846 | 148,389,364 |
YTD | 104.78 | 84.93 | - | 17.8 | 17 | 584,434 | 43,248,152 |
Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 99.79 | 97.55 | 96.08 | 88.62 | 85.26 | 0.00 | 0.00 |
| | GROWTH RATES | 5-Year Growh | R² of 5-Year Growth | 3-Year Growth |
Revenue | 0.09 | 0.3 | 0.10 |
Income | 0.06 | 0.2 | 0.00 |
Dividend | | 0.3 | 0.10 |
Capital Spending | 0.02 | NA | 0.02 |
R&D | 15.95 | NA | 17.11 |
Normalized Inc. | 22.42 | NA | 17.42 |
| | CHANGES | YTD vs. Last YTD | Curr Qtr vs. Qtr 1-Yr ago | Annual vs. Last Annual |
Revenue % | 10.4 | 9.9 | 10.1 |
Earnings % | 31.5 | 31.4 | 12.3 |
EPS % | 35.6 | 31.8 | 18.8 |
EPS $ | 0.42 | 0.14 | 0.27 |
| | SOLVENCY RATIOS | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
Net Working Capital Ratio | 37.02 |
Current Ratio | 4.6 |
Quick Ratio (Acid Test) | 3.5 |
Liquidity Ratio (Cash) | 4.56 |
Receivables Turnover | 5.0 |
Average Collection Period | 72 |
Working Capital/Equity | 65.5 |
Working Capital pS | 9.03 |
Cash-Flow pS | 2.91 |
Free Cash-Flow pS | 2.40 |
FINANCIAL STRUCTURE RATIOS |
Altman's Z-Score Ratio | 7.30 |
Financial Leverage Ratio (Assets/Equity) | 0.6 |
Debt Ratio | 31.1 |
Total Debt/Equity (Gearing Ratio) | 0.55 |
LT Debt/Equity | 0.55 |
LT Debt/Capital Invested | 37.8 |
LT Debt/Total Liabilities | 100.0 |
Interest Cover | 15.8 |
Interest/Capital Invested | 0.91 |
| | VALUATION RATIOS | MULTIPLES |
PQ Ratio | 0.00 |
Tobin's Q Ratio | 4.07 |
Current P/E Ratio - LTM | 40.70 |
Enterprise Value (EV)/EBITDA | 25.03 |
Enterprise Value (EV)/Free Cash Flow | 42.48 |
Dividend Yield | 1.4 |
Price/Tangible Book Ratio - LTM | 0.00 |
Price/Book Ratio - LTM | 7.00 |
Price/Cash Flow Ratio | 32.6 |
Price/Free Cash Flow Ratio - LTM | 39.4 |
Price/Sales Ratio | 0.00 |
P/E Ratio (1 month ago) - LTM | 23.9 |
P/E Ratio (26 weeks ago) - LTM | 22.3 |
P/E Ratio (52 weeks ago) - LTM | 20.4 |
5-Y High P/E Ratio | 52.7 |
5-Y Low P/E Ratio | 20.9 |
5-Y Average P/E Ratio | 22.3 |
Current P/E Ratio as % of 5-Y Average P/E | 35 |
P/E as % of Industry Group | 104.0 |
P/E as % of Sector Segment | 84.0 |
Current 12 Month Normalized P/E Ratio - LTM | 22.4 |
PER SHARE FIGURES |
LT Debt pS | 7.74 |
Current Liabilities pS | 2.58 |
Tangible Book Value pS - LTM | 4.43 |
Book Value pS - LTM | 14.13 |
Capital Invested pS | 21.26 |
Cash pS - LTM | 0.00 |
Cash Flow pS - LTM | 3.03 |
Free Cash Flow pS - LTM | 2.51 |
Earnings pS (EPS) | 2.42 |
| | OPERATING RATIOS | PROFITABILITY RATIOS |
Free Cash Flow Margin | 16.58 |
Free Cash Flow Margin 5YEAR AVG | 20.61 |
Net Profit Margin | 0.2 |
Net Profit Margin - 5YEAR AVRG. | 0.2 |
Equity Productivity | 1.05 |
Return on Equity (ROE) | 0.2 |
Return on Equity (ROE) - 5YEAR AVRG. | 0.2 |
Capital Invested Productivity | 0.68 |
Return on Capital Invested (ROCI) | 0.2 |
Return on Capital Invested (ROCI) - 5YEAR AVRG. | 0.1 |
Assets Productivity | 0.60 |
Return on Assets (ROA) | 0.1 |
Return on Assets (ROA) - 5YEAR AVRG. | 0.1 |
Gross Profit Margin | 58.1 |
Gross Profit Margin - 5YEAR AVRG. | 0.6 |
EBITDA Margin - LTM | 27.1 |
EBIT Margin - LTM | 21.6 |
Pre-Tax Profit Margin | 0.2 |
Pre-Tax Profit Margin - 5YEAR AVRG. | 0.2 |
Effective Tax Rate | 7.0 |
Effective Tax Rate - 5YEAR AVRG. | 12.6 |
EFFICIENCY RATIOS |
Cash Conversion Cycle | 6,127,754 |
Revenue per Employee | 339,924 |
Net Income per Employee | 56,297 |
Average Collection Period | 6,127,754 |
Receivables Turnover | 5.0 |
Day's Inventory Turnover Ratio | |
Inventory Turnover | 3.5 |
Inventory/Sales | 13.0 |
Accounts Payble/Sales | 4.49 |
Assets/Revenue | 1.67 |
Net Working Capital Turnover | 1.61 |
Fixed Assets Turnover | 1.13 |
Total Assets Turnover | 0.6 |
Revenue per $ Cash | 2.51 |
Revenue per $ Plant | 5.24 |
Revenue per $ Common Equity | 1.05 |
Revenue per $ Capital Invested | 0.68 |
Selling, General & Adm/tive (SG&A) as % of Revenue | 26.8 |
SG&A Expense as % of Revenue - 5YEAR AVRG. | 1.0 |
Research & Devlopment (R&D) as % of Revenue | 7.0 |
R&D Expense as % of Revenue - 5YEAR AVRG. | 7.0 |
|
|  





| |  |  | | |